Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DIAGNOSTIC_TEST(22)
COMBINATION_PRODUCT(10)
DRUG(10)
MIXED(8)
DNA methylation testing
5 trials
not_applicablephase_2
lei-li, peking-union-medical-college-hospital
A multi-omics analysis
3 trials
lei-li
High-risk HPV
3 trials
lei-li
TCT
3 trials
lei-li
long-acting granulocyte colony stimulating factor
2 trials
phase_3
lei-li
DNA methylation
2 trials
lei-li
Albumin-bound paclitaxel and bevacizumab
1 trial
phase_2
lei-li
Drug therapy
1 trial
phase_2
lei-li

+41 more interventions

49 unique interventions8 categories

Analytics

Trial Phases

Phase 213
Phase 34

Trial Status

Completed3
Other43

Role Distribution

Principal Investigator46
PI Rate100%

Activity Timeline

Clinical Trials (20)

NCT05310331Phase 2Unknown
Donafenib for Recurrent Cervical Cancer
Adverse EffectChemotherapyMetastatic Cervical Carcinoma+4 more
PrincipalinvestigatorStart date: 2022-03-27
NCT05310344Phase 2Unknown
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Adverse EventsAlbumin-bound PaclitaxelBevacizumab+4 more
PrincipalinvestigatorStart date: 2022-03-27
NCT05310383Phase 2Unknown
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
Anti-programmed Cell Death Receptor 1Immune Checkpoint InhibitorsImmunotherapy+7 more
PrincipalinvestigatorStart date: 2022-03-27
NCT05311566Phase 2Unknown
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Adverse EventsAnti-programmed Cell Death Receptor 1Cervical Carcinoma+6 more
PrincipalinvestigatorStart date: 2022-03-27
NCT05311579Phase 2Unknown
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Adverse EventsAnlotinibCA125+6 more
PrincipalinvestigatorStart date: 2022-03-27
NCT05310305Unknown
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Anti-programmed Death-1 AntibodyImmune Checkpoint InhibitorsMetastatic Cervical Carcinoma+7 more
PrincipalinvestigatorStart date: 2022-03-26
NCT05310318Unknown
Prognosis of Low-grade Endometrial Stromal Sarcoma
Adjuvant TherapyFertility OutcomesFertility-sparing Surgery+4 more
PrincipalinvestigatorStart date: 2022-03-26
NCT05310357Unknown
Chromosomal Instability in Ovarian Cancer
Chromosomal InstabilityEpithelial Ovarian CancerHigh-grade Serous Ovarian Carcinoma+5 more
PrincipalinvestigatorStart date: 2022-03-26
NCT05310370Unknown
HRD and Resistance to PAPPi in EOC Patients
Drug ResistanceEpithelial Ovarian CancerHomologous Recombination Deficiency+4 more
PrincipalinvestigatorStart date: 2022-03-26
NCT05309122Unknown
Cervical Cancer Screening Strategies
Cancer ScreeningCervical CancerCervical Cytology+2 more
PrincipalinvestigatorStart date: 2022-03-19

Showing 10 of 20 trials

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Francesco Perrone, M.D., Ph.D.

National Cancer Institute, Naples

Related
13 trials

Shared therapeutic areas:

Ovary CancerCancer of the Uterine CervixEndometrial Carcinoma+1 more
Similarity Score1%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Cancer of the Uterine CervixOvary CancerPD-1
Similarity Score1%

Michael S Avidan, MBBcH

Washington University School of Medicine

Related
10 trials

Shared therapeutic areas:

Quality of LifeDeep Vein Thrombosis
Similarity Score0%

You Lu, MD

West China Hospital

Related
18 trials

Shared therapeutic areas:

AnlotinibCancer of the Uterine Cervix
Similarity Score0%

Yi Chen, M.D.

General Hospital of Ningxia Medical University

Related
21 trials

Shared therapeutic areas:

Adverse EffectAdverse Event
Similarity Score0%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

Related
13 trials

Shared therapeutic areas:

Uterine Cervical DysplasiaOvary Cancer
Similarity Score0%

Mary E Charlson, MD

Weill Medical College of Cornell University

Related
20 trials

Shared therapeutic areas:

Cervical Cancer ScreeningGynecologic Cancer
Similarity Score0%

Heping Zhang, PhD

Yale University

Related
13 trials

Shared therapeutic areas:

EndometriosisPregnancy
Similarity Score0%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Cervical Carcinoma
Similarity Score0%

Seetha Shankaran, MD

Wayne State University

Related
49 trials

Shared therapeutic areas:

Pregnancy
Similarity Score0%

Publications (0)

No publications found for this investigator.

Clinical Trials (46)

Showing 20 of 46 trials

NCT05310331Phase 2PrincipalInvestigator

Donafenib for Recurrent Cervical Cancer

Adverse EffectChemotherapyMetastatic Cervical Carcinoma+4 more
Unknown
NCT05310344Phase 2PrincipalInvestigator

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

Adverse EventsAlbumin-bound PaclitaxelBevacizumab+4 more
Unknown
NCT05310383Phase 2PrincipalInvestigator

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Anti-programmed Cell Death Receptor 1Immune Checkpoint InhibitorsImmunotherapy+7 more
Unknown
NCT05311566Phase 2PrincipalInvestigator

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Adverse EventsAnti-programmed Cell Death Receptor 1Cervical Carcinoma+6 more
Unknown
NCT05311579Phase 2PrincipalInvestigator

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Adverse EventsAnlotinibCA125+6 more
Unknown
NCT05310305PrincipalInvestigator

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Anti-programmed Death-1 AntibodyImmune Checkpoint InhibitorsMetastatic Cervical Carcinoma+7 more
Unknown
NCT05310318PrincipalInvestigator

Prognosis of Low-grade Endometrial Stromal Sarcoma

Adjuvant TherapyFertility OutcomesFertility-sparing Surgery+4 more
Unknown
NCT05310357PrincipalInvestigator

Chromosomal Instability in Ovarian Cancer

Chromosomal InstabilityEpithelial Ovarian CancerHigh-grade Serous Ovarian Carcinoma+5 more
Unknown
NCT05310370PrincipalInvestigator

HRD and Resistance to PAPPi in EOC Patients

Drug ResistanceEpithelial Ovarian CancerHomologous Recombination Deficiency+4 more
Unknown
NCT05309122PrincipalInvestigator

Cervical Cancer Screening Strategies

Cancer ScreeningCervical CancerCervical Cytology+2 more
Unknown
NCT05290415PrincipalInvestigator

Host DNA Methylation for Endometrial Cancer Screening

Cancer ScreeningCervical CytologyCohort Study+3 more
Unknown
NCT05290935Phase 2PrincipalInvestigator

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Albumin-bound PaclitaxelAnti-PD-1 AntibodyChemotherapy+3 more
Unknown
NCT05290428PrincipalInvestigator

DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening

Cancer ScreeningCervical CancerCervical Intraepithelial Neoplasia+2 more
Unknown
NCT05290922PrincipalInvestigator

DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening

Cancer ScreeningCervical CytologyDNA Methylation+2 more
Unknown
NCT04664244Phase 2PrincipalInvestigator

Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Epidermal Growth Factor ReceptorNimotuzumabObjective Response Rate+4 more
Unknown
NCT04651738Not ApplicablePrincipalInvestigator

Cell-free DNA Methylation for Endometrial Cancer

Cervical CytologyDiagnostic AccuracyDNA Methylation+4 more
Unknown
NCT04646954Phase 3PrincipalInvestigator

DNA Methylation Testing for the Screening of Uterine Cervical Lesion

Cervical CancerCervical Intraepithelial NeoplasiaCytology+2 more
Unknown
NCT04650711Phase 2PrincipalInvestigator

Immunohistochemical Staining of p16 for the Screening of Cervical Cancer

Cervical Cancer ScreeningCervical Intraepithelial NeoplasiaCytology+4 more
Unknown
NCT04651920PrincipalInvestigator

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

BRCA1 MutationBRCA2 MutationChinese+4 more
Completed
NCT04651933PrincipalInvestigator

A Training Set for the HRD Model in EOC

BRCA MutationEpithelial Ovarian CancerHomologous Recombination Deficiency+3 more
Unknown